|
KMID : 0939920230550041198
|
|
대한암학회지
2023 Volume.55 No. 4 p.1198 ~ p.1209
|
|
|
Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor?Positive Metastatic Breast Cancer
|
|
Kim Seul-Gi
Kim Min-Hwan
Park Se-Jung
Kim Gun-Min
Kim Jee-Hung
Kim Jee-Ye
Kim Seong-Keun
Park Se-Ho
Park Byeong-Woo
Kim Seung-Il
Kim Soo-Jung
Jeong Joon
Lee Hye-Won
Lee Ji-Eun
Kim Hyung-Don
Jung Kyung-Hae
Sohn Joo-Hyuk
|
|
|
Abstract
|
|
|
Purpose : Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)?positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia.
Materials and Methods : Patients with HR-positive, human epidermal growth factor receptor 2?negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups.
Results : During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality.
Conclusion : Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.
|
|
|
KEYWORD
|
|
|
Palbociclib, Limited dose modification, Afebrile neutropenia, Metastatic breast cancer, Progression-free survival
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|
|